Neuren Pharmaceuticals (ASX:NEU) highlighted key updates from its partner Acadia Pharmaceuticals' (NASXDAQ:ACAD) presentation at the 44th annual J.P. Morgan Healthcare Conference.
Acadia projected that global net sales of DAYBUE (trofinetide) could reach approximately US$700 million by 2028, driven by the upcoming rollout of DAYBUE STIX, expansion of the US commercial team, and international market growth.
Since its US launch in 2023, DAYBUE has been administered to more than 2,000 patients with Rett syndrome, with 12-month treatment persistency rising to 55%.
Over 300 patients are currently enrolled in Acadia's real-world LOTUS study.
The US rollout of the new DAYBUE STIX powder formulation began in Q1 2026, with full availability expected by Q2 2026.